MKI67 and neoplasm: estimated that many non-cycling tumor cells express Ki67 in at least one-third of CRCs cases. These Ki-67-positive non-cycling tumor cells may be more stable than tumor cells that fail to achieve cell cycle arrest and thus may be more resistant to adjuvant therapy or the patient’s immune response (25).